Post by
hoffbag on May 15, 2021 6:27pm
15 years ago.....and counting.
Gilles Gagnon Joins Ceapro Board Download as PDFSeptember 11, 2007 EDMONTON, ALBERTA -- (MARKET WIRE) -- 09/11/07 -- Ceapro Inc. (TSX VENTURE: CZO) a Canadian growth-stage biotechnology company is delighted to announce that Gilles Gagnon, with 25 years experience in healthcare and pharmaceutical organizations, most recently as President and CEO of AEterna Zentaris, has joined the Board, effective immediately. His extensive managerial experience, especially in mergers and acquisitions, as well as his inside knowledge of the pharma world will aid Ceapro in executing its growth strategy - to be a global leader in developing and commercializing products for human and animal health markets. "Ceapro is a promising company with a compelling story of innovation in health-based technologies based on solid science," said Gilles Gagnon. "They are moving from pure research in natural ingredients, through product development to international commercialization." Added Ceapro Chairman Ed Taylor, "With Gilles's hands-on experience, we will develop our vision into viable business practices, focusing on bringing Ceapro to the next level of success and business maturity - as a global biotechnology company." This Board position is being filled as John Yewchuk, President and CEO of Thermo King Western Ltd, who has been on Ceapro's board since 1999, is stepping down. His important contribution over the years is well appreciated. About Gilles Gagnon Prior to forming his pharmaceutical consultancy firm, Prodev Pharma Inc., Gilles Gagnon held several senior executive positions: President and COO, then CEO at AEterna Zentaris; VP External Affairs at Novartis Pharmaceuticals; Executive Director, Corporate Planning and Administration at Sandoz Canada, Inc., to name a few. Throughout his career, in addition to general management functions, he has been particularly involved in corporate development, alliance management, as well as marketing functions. In this capacity he participated in the launch of nine innovative pharmaceutical products. He has also participated in several international committees and strategic advisory boards, holds post-graduate degrees in pharmacology (M.Sc.) and administration (M.B.A) from the Universit1/2 de Sherbrooke, as well as a certificate in General Management from the London Business School, UK. About Ceapro Inc. Ceapro Technology Inc., Ceapro Veterinary Products Inc., Ceapro Active Ingredients Inc. and Ceapro Bioenergy Inc. are wholly owned subsidiaries of Ceapro Inc., which is a Canadian growth-stage biotechnology company. Our primary business activities relate to the development and commercialization of organic products for medical, cosmetic and animal health industries using proprietary technology and natural, renewable resources. We will be applying our technology to become an active participant in the bioenergy sector. We have also introduced health and wellness services employing our CeaProve diagnostic technology. Ceapro shares trade on the Canadian TSX Venture Exchange under the symbol CZO. To learn more about Ceapro, visit www.ceapro.com Contacts: Ceapro Inc. Dr. Mark Redmond President and CEO
Comment by
prophetoffacts on May 15, 2021 6:59pm
This post has been removed in accordance with Community Policy
Comment by
prophetoffacts on May 16, 2021 12:12pm
This post has been removed in accordance with Community Policy
Comment by
hoffbag on May 16, 2021 12:41pm
Strong belief doesn't mean actual result. 7 months left in the year...... Still don't see any revenue numbers attached to those actions or any boxes checked to date.
Comment by
Ciao on May 16, 2021 1:04pm
With all the near greatness in sight 1) why is this trading at a market cap of $50M (ie. Burcon with much less is at $400M plus) 2) why haven't insiders stepped in to purchase undervalued shares?